In a recent interview on Proactive with Steve Darling, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, announced that their COVID-19 vaccine, TNX-1800, has been selected for testing in Project Next Gen. This program is managed by the White House and the Department of Health and Human Services, NIH, and NIAID.

The TNX-1800 vaccine uses a live virus platform to stimulate the immune system in a unique way. This method offers longer-lasting and potentially transmission-blocking immunity compared to mRNA vaccines. The selection of TNX-1800 for this program is a result of Tonix Pharmaceuticals’ almost ten years of dedication to vaccine development.

Furthermore, the technology platform can be adapted to protect against other infectious diseases such as monkeypox, smallpox, and tuberculosis. This choice represents the importance of vaccine platforms in addressing various infectious threats. Tonix’s approach offers the promise of more durable immunity and potential transmission prevention, potentially revolutionizing our approach to infectious disease control. The platform’s adaptability makes it a valuable tool for future vaccine strategies, making it a versatile solution for future pandemics.

For more information about Tonix Pharmaceuticals and their COVID-19 vaccine TNX-1800, please contact Proactive Studio at +1 347-449-0879 or email them at na-editorial@proactiveinvestors.com.